

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/13/2012; Page 1

Suggested Formula	Nalbuphine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 50 mL)	FIN	F 005 050v2
----------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Nalbuphine Hydrochloride	0.500	g				
Sodium Chloride, USP	0.29	g				
Benzyl Alcohol, NF	0.5	mL				
Sterile Water for Injection, USP	40.0	mL				
Sterile Water for Injection, USP	q.s. to 50.0	mL				
Hydrochloric Acid 1N Solution	As required		8			

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information	
Light sensitive (protect from li	ght whenever possible): Nalbuphine Hydrochloride, Benzyl Alcohol
Suggested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
Processing Error / Testing Considerations:	To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 797</i> . Only trained and qualified personnel must prepare this formula.
	All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.
	Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.
	Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.
	Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/13/2012; Page 2

Suggested Formula	Nalbuphine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 50 mL)	FIN	F 005 050v2
----------------------	---	-----	-------------

SUGGESTED PREPARATION (for 50 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Nalbuphine Hydrochloride §	0.500	g			
Sodium Chloride, USP §	0.29	g			
Benzyl Alcohol, NF §	0.5	mL			
Sterile Water for Injection, USP §	40.0	mL	(A)		
Sterile Water for Injection, USP §	q.s. to 50.0	mL			
Hydrochloric Acid 1N Solution §	As required				

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. **Equipment sterilization:**

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.

2. **Powder-liquid preparation:**

- A. In the given order, sequentially add the following ingredients to the Sterile Water for Injection (40.0 mL *plus* processing error adjustments).
 - -Benzyl Alcohol
 - -Sodium Chloride
 - -Nalbuphine Hydrochloride

Specifications: Continuously mix until all solid particles have completely dissolved.

End result: Homogeneous liquid-like solution.

Note: Add the next ingredient, once the previous one has been completely added and dissolved.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/13/2012; Page 3

Suggested Formula

Nalbuphine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 50 mL)

FIN

F 005 050v2

3. **pH testing:**

- A. Draw an appropriate amount of the mixture (Step 2A).
- B. Test the pH of the sample. It should lie between 3.5 and 3.7.
- C. If the pH > 3.7, carefully add, in a dropwise fashion, the Hydrochloric Acid 1N Solution to the mixture:
 - 1. Draw and transfer 1 or 2 drops of the Hydrochloric Acid 1N Solution to the mixture.
 - 2. Stir for at least 5 minutes to evenly disperse the Hydrochloric Acid 1N Solution.
 - 3. Re-test the pH.
 - 4. Continue to add the Hydrochloric Acid 1N Solution until the pH of 3.5 to 3.7 is obtained.

IMPORTANT: Do not allow the pH to fall below 3.5.

4. **Filling to volume:**

A. Add additional Sterile Water for Injection to the above mixture to fill to the required batch size (50.0 mL *plus* processing error adjustments).

Specification: Continuously mix

End result: Homogeneous liquid-like solution

5. **Filtering and transferring:**

Aseptically filter the required amount of solution through a 0.22-µm sterile filter into the recommended dispensing containers (see Packaging requirements) and sample containers for sterility and endotoxin testing.

6. Filter integrity test:

Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

7. Sterility testing:

Validate the Test samples for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

6/13/2012; Page 4

Suggested Formula	Nalbuphine Hydrochloride 10 mg/mL Intravenous Injection (Solution, 50 mL)	FIN	F 005 050v2	
----------------------	---	-----	-------------	--

SUGGESTED PRESENTATION

JGGESTED PRI	_JL	MIATION				
Estimated Beyond-Use Date			ckaging rements	Sterile, tightly closed, light-resistant unit dose injection vials.		
	1	Use as directed. Do not exceed prescrib dose.	ed 8	Do not used if product changes color.		
	2	Keep out of reach of children.	9	Protect from light.		
	3	Keep refrigerated. Do not freeze.	10	For medical office use only.		
Auxiliary Labels	4	Consult your health care practitioner if a other prescription or over-the-coun medications are currently being used or a prescribed for future use.	ter	Nalbuphine hydrochloride should be administered as a supplement to general anesthesia only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. Naloxone, resuscitative and intubation equipment and oxygen should be readily available.		
	5	Discard in the presence of particular matter.	ite 12	May produce psychological and/or physical dependence.		
	6	Do not take with alcohol, sleep aid tranquilizers or other CNS depressants.		May impair mental and/or physical ability. Use care when operating a car or machinery.		
	7	Discard container after use.	14	Equilibrate to room temperature before use.		
Pharmacist Instructions	Add any auxiliary labels specific to the active ingredients to the dispensing container as deemed necessary.					
Patient Instructions	Contact your pharmacist in the event of adverse reactions					

REFERENCES

1.	Parenteral Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 313.
2.	Nalbuphine Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition.</i> London, England: The Pharmaceutical Press; 2009: 91.
3.	Nalbuphine (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #6357.
4.	USP <797>. <i>United States Pharmacopeia XXXV / National Formulary 30</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2012: 350.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.